Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

The investigational therapy was safe, well-tolerated, and showed promising improvements in cognitive measures among patients with dementia with Lewy bodies.

CT1812 Meets Primary End Point in Phase 2 SHIMMER Study for Dementia with Lewy Bodies

Human studies revealed thinner myelin sheaths in CD59-deficient patients, indicative of a process of segmental demyelination followed by remyelination.

Preclinical Study Links CD59 Deficiency to Demyelination and Conduction Blocks

Videos

Neurology News Network. for the week ending December 21, 2024. [WATCH TIME: 4 minutes]

FDA Places Hold on CONNECT2-EDO51, Sevasemten Meets End Point in Becker, Tolebrutinib Gets Breakthrough Therapy Designation

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 20, 2024. 

NeurologyLive® Friday 5 — December 20, 2024

Assistant professor of neurosurgery and neuroscience at Mayo Clinic Arizona

The assistant professor of neurosurgery and neuroscience at Mayo Clinic Arizona discussed an ongoing early-stage study assessing the therapeutic potential of NRTX-1001 nerve cell therapy in drug-resistant unilateral mesial temporal lobe epilepsy. [WATCH TIME: 5 minutes]

Studying Nerve Cell Therapy NRTX-1001 to Treat Mesial Temporal Lobe Epilepsy: Jonathan Parker, MD, PhD

, has been with the team since September 2022. Follow her on Twitter 

The program assembles a collaborative team of in-house and external experts in research, clinical care, and regulatory affairs to navigate gene therapy programs through the drug development process.

FDA Grants MDA Kickstart Program Rare Pediatric Disease Designation and Orphan Drug Designation in Congenital Myasthenic Syndrome

IJMSC Insights offers a closer look at the latest research and the people behind it from the community of the International Journal of Multiple Sclerosis Care (IJMSC) and the Consortium of Multiple Sclerosis Centers (CMSC).

IJMSC Insights: Blanca De Dios Perez on Employment and Multiple Sclerosis

Pediatric epilepsy specialist at University of California, San Francisco.

At AES 2024, a duo of pediatric epilepsy specialists discussed how implementation science, validated blood biomarkers, and cross-disciplinary collaboration are advancing epilepsy care and closing research gaps. [WATCH TIME: 3 minutes]

Advancing Epilepsy Research Through Implementation Science and Biomarkers: Adam Numis, MD; Laura Kirkpatrick, MD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AANEM 2024

AES 2024

CTAD 2024

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Introduction to CMSC Best Practices in Multiple Sclerosis Therapies Roundtable 

Best Practices in Multiple Sclerosis

Best Practices in Multiple Sclerosis: Discussion

Best Practices for Therapeutic Selection in Relapsing Multiple Sclerosis

Therapeutic Selection in Relapsing Multiple Sclerosis: Key Concepts

Best Practices for Therapeutic Selection in Relapsing Multiple Sclerosis: Discussion

Therapeutic Selection for Progressive Multiple Sclerosis

Considerations in Therapeutic Selection for Progressive Multiple Sclerosis

Therapeutic Selection for Progressive Multiple Sclerosis: Discussion

Patients With Features of Aggressive Multiple Sclerosis or Poor Prognosis

Safety Concerns and Discussion: Highly Active Multiple Sclerosis

Therapeutic Goals of Treating Multiple Sclerosis 

Indicators of Suboptimal Therapies 

Therapeutic Selection in Pediatric-Onset Multiple Sclerosis

Best Practices for Treating Pediatric Patients

Therapeutic Selection in Pediatric-Onset Multiple Sclerosis: Discussion 

Best Practices for DMTs for Pregnant Patients With Multiple Sclerosis  

Multiple Sclerosis Drugs During Pregnancy 

Relapse Therapy and Postpartum Care for Pregnant Patients With Multiple Sclerosis 

Monitoring Efficacy of Treatment in Patients With Multiple Sclerosis 

Discussion: Monitoring Efficacy of Treatment in Patients With Multiple Sclerosis

Issues in Therapeutic Selection for Multiple Sclerosis 

Considerations When Selecting an Optimal DMT for Multiple Sclerosis Treatment 

Best Practices in Multiple Sclerosis Therapies: Future Perspectives

Expert Insights on the Best Practices of Multiple Sclerosis: Summary

Closing Thoughts: CMSC Best Practices in Multiple Sclerosis Therapies Roundtable

An expert-led panel discuss the best practices and different treatment considerations in multiple sclerosis.

Clinical

EMD-22-NRD0193 - /clinical/multiple-sclerosis

CMSC Best Practices in Multiple Sclerosis Therapies Roundtable